Tenax Therapeutics (NASDAQ:TENX) Research Coverage Started at Cantor Fitzgerald
by Scott Moore · The Cerbat GemCantor Fitzgerald assumed coverage on shares of Tenax Therapeutics (NASDAQ:TENX – Free Report) in a research report sent to investors on Tuesday, Marketbeat reports. The brokerage issued an overweight rating and a $35.00 price target on the specialty pharmaceutical company’s stock.
Other equities research analysts have also issued research reports about the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Tenax Therapeutics in a report on Monday, December 22nd. Guggenheim raised their target price on Tenax Therapeutics from $25.00 to $34.00 and gave the stock a “buy” rating in a research note on Monday. Lifesci Capital upgraded Tenax Therapeutics to a “strong-buy” rating in a report on Thursday, March 12th. Finally, William Blair reiterated an “outperform” rating on shares of Tenax Therapeutics in a report on Tuesday, March 10th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Tenax Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $29.67.
View Our Latest Research Report on Tenax Therapeutics
Tenax Therapeutics Price Performance
Shares of Tenax Therapeutics stock opened at $14.91 on Tuesday. Tenax Therapeutics has a one year low of $4.63 and a one year high of $18.38. The business’s 50 day simple moving average is $13.51 and its two-hundred day simple moving average is $10.21. The stock has a market capitalization of $93.10 million, a P/E ratio of -11.21 and a beta of 1.41.
Tenax Therapeutics (NASDAQ:TENX – Get Free Report) last released its quarterly earnings data on Tuesday, March 10th. The specialty pharmaceutical company reported ($0.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.26) by $0.88. Sell-side analysts expect that Tenax Therapeutics will post -0.88 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Tenax Therapeutics
Institutional investors and hedge funds have recently made changes to their positions in the business. Virtu Financial LLC bought a new position in Tenax Therapeutics in the 3rd quarter worth about $92,000. Letko Brosseau & Associates Inc. bought a new stake in Tenax Therapeutics during the 4th quarter valued at about $130,000. Corient Private Wealth LLC bought a new stake in Tenax Therapeutics during the 4th quarter valued at about $151,000. Quadrature Capital Ltd purchased a new position in Tenax Therapeutics in the fourth quarter worth about $252,000. Finally, Goldman Sachs Group Inc. purchased a new position in Tenax Therapeutics in the fourth quarter worth about $273,000. Institutional investors own 1.67% of the company’s stock.
Tenax Therapeutics Company Profile
Tenax Therapeutics, Inc is a clinical-stage specialty pharmaceutical company developing drug delivery technologies designed to improve pain management in acute care settings. The company’s proprietary platform leverages biodegradable polymer matrices to create sustained-release formulations of local anesthetics, aiming to extend the duration of pain relief while reducing reliance on opioid medications.
Tenax’s lead development programs focus on injectable formulations intended for infiltration and peripheral nerve block applications, with the goal of providing longer-lasting analgesia following surgical and procedural interventions.